Media Relations:

(+) 33 1 53 77 46 46

Investor Relations:

(+) 33 1 53 77 45 45

Sanofi: Q1 2013 business EPS(1) impacted by exclusivity losses in prior year
Growth platforms(2) sales increased 8.6%(3)

PARIS, May 2, 2013 /PRNewswire/ — Sanofi (NYSE: SNY; EURONEXT: SAN)

  Q1 2013 Change (reported) Change (CER)
Net sales €8,059m -5.3% -2.8%
Business net income(1) €1,613m -33.5% -28.8%
Business EPS(1) €1.22 -33.3% -29.0%

In order to facilitate an understanding of our operational performance, we comment on our business net income statement. Business net income(1) is a non-GAAP financial measure. The consolidated income statement for Q1 2013 is provided in Appendix 4 and a reconciliation of business net income to consolidated net income in Appendix 3. Consolidated net income for Q1 2013 was €1,004 million, compared to €1,809 million for Q1 2012. Consolidated EPS for Q1 2013 was €0.76 versus €1.37 for Q1 2012.

Commenting on the Group’s performance in Q1 2013, Sanofi Chief Executive Officer, Christopher A. Viehbacher said,
“As expected, the loss of exclusivity of Plavix®, Avapro® and Eloxatin® in the course of 2012 in the U.S. had a negative impact on Q1 results. However, our growth platforms(2) continue to deliver strong results with diabetes, vaccines, and Genzyme all achieving double-digit growth. The early launch trends for Aubagio® and Auvi-Q™ in the U.S. are encouraging, regulatory approvals were granted for Lyxumia®, Zaltrap® and Hexyon™ in the EU, and we received positive CHMP opinion for Aubagio®. Moreover, we look forward to the Phase III data releases for several pipeline projects later this year, including our new insulin glargine formulation and alirocumab. The Group expects to resume growth in the second half of 2013.”

Q1 2013 Performance

R&D Update

2013 Guidance

(1) See Appendix 6 for definitions of financial indicators (page 18 at; (2) See page 2 at; (3) Growth in net sales is expressed at constant exchange rates (CER) unless otherwise indicated (see Appendix 6, page 18 at, for a definition); (4) See definition on page 7 at; (5) Genzyme consists of rare diseases products and multiple sclerosis products; (6) 2012 business EPS with the retroactive application of IAS19R was €6.14.

To access the full press release of the Q1 2013 results, please click here:

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Interview with Jérôme Contamine

View with Windows Media Player
View with Adobe Flash Player

Photo Gallery

Christopher A. Viehbacher, Chief Executive Officer
Christopher A. Viehbacher, Chief Executive Officer
Jérôme Contamine, Executive VP, Chief Financial Officer
Jérôme Contamine, Executive VP, Chief Financial Officer
Hanspeter Spek, President, Global Operations
Hanspeter Spek, President, Global Operations
Dr. Elias Zerhouni, Global President of R&D
Dr. Elias Zerhouni, Global President of R&D
Olivier Charmeil, Senior Vice President, Vaccines
Olivier Charmeil, Senior Vice President, Vaccines

Download Documents

Related Links
Sanofi Investor Relations/2013 Q1 Results
Sanofi US Website